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Abstract (Maximum: 300 words; current: 300 words) 49 
Background: Duration of prior hormonal treatment can predict response to 50 
subsequent therapy in patients with metastatic castration-resistant prostate cancer 51 
(mCRPC).  52 
Objective: To determine if prior endocrine therapy duration is an indicator of 53 
abiraterone acetate (AA) sensitivity.  54 
Design, setting, and participants: Post hoc exploratory analysis of randomised 55 
phase 3 studies examining post-docetaxel (COU-AA-301) or chemotherapy-naïve 56 
mCRPC (COU-AA-302) patients receiving AA. Treatment effect on overall survival 57 
(OS), radiographic progression-free survival (rPFS), and prostate-specific antigen 58 
(PSA) response analysed by quartile duration of prior gonadotropin-releasing 59 
hormone agonists (GnRHa) or androgen receptor (AR) antagonist.  60 
Intervention: Patients randomised to AA (1000 mg, orally once daily) plus 61 
prednisone (5 mg, orally twice daily) or placebo plus prednisone. Prior endocrine 62 
therapy was GnRHa (COU-AA-301, n = 1127 [94%]; COU-AA-302, n = 1057 [97%], 63 
45.1 or 36.7 mo median duration, respectively) and/or orchiectomy (COU-AA-301, n 64 
= 78 [7%)] COU-AA-302, n = 44 [4%]; castrated patients received prior AR 65 
antagonists (COU-AA-301, n = 1015 [85%]; COU-AA-302, n = 1078 [99%], 15.7 or 66 
16.1 mo median duration, respectively). 67 
Outcome measurements and statistical analysis: Cox model used to obtain HR 68 
and associated 95% CI with statistical inference by log rank statistic. 69 
Results and limitations: Clinical benefit with AA was observed for OS, rPFS, and 70 
PSA response for nearly all quartiles with GnRHa or AR antagonists in both COU-71 
AA-301 and COU-AA-302. In COU-AA-301, patients with longer duration of prior 72 
endocrine therapy tended to have greater AA OS, rPFS, and PSA response benefit, 73 
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with lead-time chemotherapy bias potentially impacting COU-AA-301 results. Time to 74 
castration resistance was not captured. This analysis is limited as a post hoc 75 
exploratory analysis. 76 
Conclusions: In the COU-AA-301 and COU-AA-302 studies, AA produced clinical 77 
benefit regardless of prior endocrine therapy duration in patients with mCRPC.  78 
Patient Summary: mCRPC patients derived clinical benefit with AA regardless of 79 
prior endocrine therapy duration. 80 
  81 
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1. Introduction  82 
Most tumours in men who present with metastatic disease at prostate cancer 83 
diagnosis or with disease recurrence after potentially curative local therapy respond 84 
to androgen deprivation [1] with luteinising hormone–releasing hormone agonists or 85 
antagonists or bilateral orchiectomy, and to first-line androgen receptor antagonists 86 
such as bicalutamide [2-5]. In most cases, however, the response is not durable and 87 
virtually all tumours eventually progress to a lethal castration-resistant phenotype 88 
[1,5]. 89 
 90 
Abiraterone acetate, a prodrug of abiraterone that is a selective inhibitor of CYP17 91 
[6,7], administered in combination with prednisone/prednisolone (hereafter referred 92 
to as abiraterone) is one of several agents indicated for the treatment of patients with 93 
metastatic castration-resistant prostate cancer [8-17]. Abiraterone significantly 94 
improved overall survival and all secondary and tumour-specific endpoints [9,10], as 95 
well as patient-reported fatigue [18] and quality of life [19] in the phase 3 COU-AA-96 
301 trial in patients with metastatic castration-resistant prostate cancer progressing 97 
after docetaxel chemotherapy. A similar survival benefit was observed in the pre-98 
chemotherapy COU-AA-302 study along with a significant improvement in 99 
radiographic-free survival, all secondary endpoints, and patient-reported outcomes. 100 
[8,11,16].  101 
 102 
Previous data suggest that the duration of prior hormonal treatment predicts duration 103 
to subsequent hormone therapy [20,21]: the longer duration of the response to the 104 
first androgen depletion therapy, the longer the duration of response to the second 105 
including CYP17 inhibitors [20] such as abiraterone and ketoconazole [21]. Here we 106 
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report a post hoc analysis to determine whether the duration of prior endocrine 107 
therapy with gonadotropin-releasing hormone (GnRH) agonists or first-generation 108 
androgen receptor antagonists was associated with overall survival, radiographic 109 
progression-free survival, or prostate-specific antigen (PSA) response rate in 110 
patients treated with abiraterone acetate plus prednisone in the post- or the pre-111 
chemotherapy COU-AA-301 and COU-AA-302 trials.  112 
 113 
2. Patients and methods 114 
COU-AA-301 (NCT00638690) [9,10] and COU-AA-302 (NCT00887198) [8,11,16] 115 
were phase 3, multinational, randomised, double-blind, placebo-controlled studies of 116 
post-docetaxel and chemotherapy-naïve patients, respectively, with progressive 117 
metastatic castration-resistant prostate cancer (Fig. 1). The review boards at all 118 
participating institutions approved the studies, which were conducted according to 119 
the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines 120 
of the International Conference on Harmonisation. All patients provided written 121 
informed consent to participate in the studies. In COU-AA-301 and COU-AA-302, 122 
patients were randomised 2:1 and 1:1, respectively, to oral abiraterone acetate 1 g 123 
daily and prednisone 5 mg twice daily versus placebo and prednisone 5 mg twice 124 
daily. Prednisolone at the same dose was used in place of prednisone at some sites. 125 
Patients received continuous GnRH agonist if they had not undergone a surgical 126 
orchiectomy to maintain serum testosterone <50 ng/dl. Prior endocrine therapies 127 
included GnRH agonists and androgen receptor antagonists as defined in 128 
Supporting Table 1. Duration of prior endocrine therapy from the start of endocrine 129 
therapy to the date of randomization as documented in the case report forms was 130 
recorded for each patient and categorised by quartiles as defined in Tables 1 and 2 131 
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and Figures 2 and 3. Associations with clinical outcomes in the COU-AA-301 and 132 
COU-AA-302 studies were associated by quartiles. A study monitor had access to 133 
the patients’ medical records and was responsible for verifying adherence to the 134 
study protocols. 135 
 136 
Distributions of time-to-event variables were estimated using the Kaplan-Meier 137 
product limits method. The log-rank statistic was used as the primary analysis for 138 
treatment comparison. Cox model analysis was used to obtain the hazard ratio and 139 
its associated 95% confidence interval. Data shown for COU-AA-301 represent the 140 
final analysis of the study before patient crossover from prednisone to abiraterone 141 
(775 of the expected 797 death events), with a median follow-up for overall survival 142 
of 20.2 mo. Data shown for COU-AA-302 (ie, radiographic progression-free survival 143 
and PSA response rate) represent mature data obtained at the third interim analysis 144 
conducted at 56% of the expected death events, whereas mature overall survival 145 
data were obtained at the final analysis. Results were considered significant if p ≤ 146 
0.05; no multiplicity adjustments were made for this hypothesis generating post hoc 147 
analysis. An interaction test was performed to assess whether the effect of 148 
abiraterone acetate was dependent on prior endocrine therapy duration. This 149 
analysis was performed for GnRH agonists given the majority of patients received 150 
prior GnRH agonists (Supporting Table 2). 151 
 152 
3. Results 153 
3.1. Patient characteristics 154 
Patients received prior endocrine therapy with GnRH agonists (COU-AA-301, n = 155 
1127 [94%]; COU-AA-302, n = 1057 [97%]) and/or orchiectomy (COU-AA-301, n = 156 
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78 [6.5%]; COU-AA-302, n = 44 [4.1%]) (Fig. 1). Pure androgen receptor antagonists 157 
(COU-AA-301, n = 1015 [85%]; COU-AA-302, n = 1078 [99%]) were also used in 158 
COU-AA-302. In COU-AA-301, median duration of prior GnRH agonist and androgen 159 
receptor antagonist exposure was 45.1 mo and 15.7 mo, respectively. Median 160 
durations of prior GnRH agonist and androgen receptor antagonist exposure in 161 
COU-AA-302 were 36.7 mo and 16.1 mo, respectively. These durations represent 162 
duration of prior endocrine therapies, not a single exposure to one form of 163 
manipulation. 164 
 165 
3.2. Outcomes 166 
Median overall survival was longer in the abiraterone group versus the prednisone 167 
group in all quartiles of duration of prior endocrine therapy studied in COU-AA-301 168 
(Table 1 and Supporting Fig. 1) and all except quartile 3 in COU-AA-302 (Table 2 169 
and Supporting Fig. 2). However, there were inconsistencies across quartiles in 170 
demonstrating a significant treatment benefit with abiraterone acetate in this post hoc 171 
exploratory analysis. In both trials, patients who experienced longer duration (quartile 172 
4 equals longest duration) of prior endocrine therapy had longer overall survival, 173 
whether measured against quartile exposure of GnRH agonists or androgen receptor 174 
antagonists. This was observed regardless of assignment with few exceptions for 175 
both the abiraterone and prednisone groups. 176 
 177 
Radiographic progression-free survival was significantly longer in the abiraterone 178 
group versus the prednisone group in patients for all quartiles of prior GnRH agonists 179 
or androgen receptor antagonists treatment in both COU-AA-301 (Table 1 and Fig. 180 
2) and COU-AA-302 (Table 2 and Fig. 3). The PSA response proportions were also 181 
9 
 
 
superior independent of the type and duration of prior endocrine therapy (Fig. 4A, 182 
Fig. 4B). 183 
 184 
Results from an interaction analysis to examine whether the effect of abiraterone 185 
was dependent on prior endocrine therapy duration were not significant in both COU-186 
AA-301 and COU-AA-302 for both overall survival and radiographic progression-free 187 
survival (Supporting Table 2). Analysis by GnRH agonist quartiles yielded similar 188 
results, with none of the interaction tests on outcome measures showing 189 
significance. 190 
 191 
Treatment with abiraterone acetate and prednisone was well tolerated by patients, 192 
as previously reported for both COU-AA-301 [9,10] and COU-AA-302 [8,11,16]. 193 
 194 
4. Discussion 195 
Clinical benefit of abiraterone was maintained regardless of type and duration of 196 
prior endocrine therapy at nearly all quartiles examined, as shown in this post hoc 197 
analysis of the phase 3 COU-AA-301 and COU-AA-302 studies in patients with 198 
metastatic castration-resistant prostate cancer progressing post docetaxel or without 199 
prior chemotherapy, respectively. The clinical benefit of abiraterone was maintained 200 
despite the fact that longer exposure of prior endocrine therapy in COU-AA-301 and 201 
COU-AA-302 was associated with a longer time to death and radiographic 202 
progression-free survival regardless of treatment assignment. The results show the 203 
importance of considering the duration of prior hormone therapy in trial design, both 204 
as a stratification factor, and predictive factor in the evaluation of patients with CRPC 205 
who are progressing in the pre- or post-chemotherapy setting. When interpreting 206 
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these results, it should be evident that prior endocrine therapy exposure in the 207 
setting of this post hoc analysis equates with duration of prior hormone therapy and 208 
not with hormone sensitivity or hormone response. 209 
 210 
Previous data using other hormonal agents suggested that a short response to first-211 
line androgen deprivation therapy predicts poor response both in frequency and 212 
duration to a subsequent hormone therapy [20-23]. In one retrospective study of 57 213 
patients with progressing CRPC treated with post-docetaxel enzalutamide from the 214 
AFFIRM trial, the median time to progression-free survival was significantly shorter 215 
(2.8 mo vs 8.6 mo, p = 0.002) and PSA response rate was significantly lower (8% vs 216 
58%, p < 0.001) in patients with a less than 12 month versus greater than 12 month 217 
median duration of response to first-line ADT [22]. The results are consistent with the 218 
current analysis which showed that the patients in the lowest quartile of duration of 219 
prior endocrine therapy had the shortest overall survival and radiographic 220 
progression-free survival. The effects of abiraterone acetate and prednisone, 221 
however, were seen in patients with short and long durations of exposure by quartile 222 
with the exception of the lowest quartile for overall survival and radiographic 223 
progression-free survival in COU-AA-301. This is consistent with results shown in a 224 
single-site analysis limited to 37 patients with metastatic castration-resistant prostate 225 
cancer post-docetaxel with varying duration of enzalutamide therapy, in which PSA 226 
response to subsequent abiraterone was similar for patients who received 227 
enzalutamide for ≤3 mo or >3 mo [24]. As reported recently [23], earlier treatment 228 
with docetaxel might not have a large impact on the subsequent activity of hormonal 229 
treatment, as comparable outcomes from enzalutamide after abiraterone were 230 
observed irrespective of prior docetaxel use [25]. Cabazitaxel was also shown to 231 
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significantly improve overall survival compared with mitoxantrone regardless of the 232 
duration of prior androgen deprivation therapy separated by tertiles of <2.5 yr, 2.5–233 
5.0 yr, and ≥5 yr [26]. Although beyond the scope of this study, it would be of clinical 234 
value to examine whether patients with a particular duration of prior endocrine 235 
therapy before developing castration resistance might be optimally sequenced with a 236 
particular second-line treatment whether abiraterone acetate plus prednisone versus 237 
enzalutamide versus docetaxel.  238 
The current study has several important limitations. Some patients might have 239 
received short courses of androgen receptor antagonists to prevent tumour flare in 240 
the castrate setting. This short course of therapy would not necessarily be expected 241 
to affect outcomes. There is also uncertainty with respect to the analysis of the 242 
lowest quartile with presumably more aggressive disease as evidenced by short 243 
duration of 0–12 months of prior GnRH agonist therapy, as the number of patients in 244 
this group was too low to analyse definitively. An additional concern is whether 245 
duration of exposure is an appropriate surrogate for sensitivity, given that there are 246 
no standards for reporting the response to ADT. Time to castration resistance, which 247 
probably better describes sensitivity to ADT, could not be tested as a potential 248 
predictor of abiraterone clinical benefit in this study because this parameter was not 249 
available in the database. It should be noted that in the current study duration of prior 250 
hormonal treatment comprised time to castration resistance and time with castration 251 
resistance on hormonal treatment. Moreover, onset of castration resistance could 252 
have started earlier than indicated by the addition of abiraterone acetate and 253 
prednisone, reflecting individual physicians’ management philosophy and 254 
preferences. The effects of abiraterone acetate and prednisone on further outcome 255 
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are valid given that patients were randomized between the two treatment groups, as 256 
this analysis is reporting phase 3 randomized trials.  257 
 258 
5. Conclusion 259 
In general, the efficacy outcomes favoured the abiraterone treatment groups 260 
compared with prednisone groups regardless of prior endocrine therapy exposure in 261 
metastatic castration-resistant prostate cancer patients either post docetaxel or 262 
without prior chemotherapy. Consistent with other studies, longer duration of prior 263 
endocrine therapy in less pre-treated patients (ie, chemotherapy-naive) tended to 264 
have greater benefit. There were too few patients in the subgroup with short initial 265 
sensitivity to androgen deprivation (eg, 6-12 months) to draw the definitive 266 
conclusion highlighting the need of further studies in this specific patient population. 267 
 268 
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Figure Legends 406 
Fig.1 – Consolidated Standards of Reporting Trials diagram. 407 
Fig. 2 – Radiographic progression-free survival Kaplan-Meier estimates in 408 
COU-AA-301 patients with prior endocrine therapy exposure by duration in 409 
quartiles. A. Gonadotropin-releasing hormone agonists; B. androgen receptor 410 
antagonists. AA = abiraterone acetate; CI = confidence interval; HR = hazard 411 
ratio; P = prednisone; rPFS = radiographic progression-free survival; Q = 412 
quartile. 413 
Fig. 3 – Radiographic progression-free survival Kaplan-Meier estimates in 414 
COU-AA-302 patients with prior endocrine therapy exposure by duration in 415 
quartiles. A. Gonadotropin-releasing hormone agonists; B. androgen receptor 416 
antagonists. AA = abiraterone acetate; CI = confidence interval; HR = hazard 417 
ratio; P = prednisone; rPFS = radiographic progression-free survival; Q = 418 
quartile. 419 
Fig. 4 – A. Prostate-specific antigen response in COU-AA-301 patients with 420 
prior endocrine therapy exposure by duration in quartiles. B. Prostate-specific 421 
antigen response in COU-AA-302 patients with prior endocrine therapy 422 
exposure by duration in quartiles. AA = abiraterone acetate; GnRH = 423 
gonadotropin-releasing hormone; P = prednisone; PSA = prostate-specific 424 
antigen; Q = quartile. 425 
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Table 1 – Clinical outcomes in COU-AA-301 patients with prior endocrine therapy exposure by duration in quartiles 426 
 GnRH agonists 
 Q1 
≤28 mo 
Q2 
≥29 to ≤45 mo 
Q3 
≥46 to ≤71 mo 
Q4 
>71 mo  
Treatment AA + P P AA + P P AA + P P AA + P P 
 (n = 191) (n = 87) (n = 174) (n = 109) (n = 191) (n = 91) (n = 195) (n = 89) 
 Overall survival 
HR  0.99 
(0.71–1.37) 
0.9 
0.61 
(0.46–0.82) 
0.001 
0.73 
(0.53–1.00) 
0.05 
0.68 
(0.48–0.97) 
0.03 
(95% CI)  
p Value 
Median, mo  12.2 11.1 14.4 9.1 16.8 11.2 19.6 15.9 
(95% CI) (10.5–14.9) (8.3–14.4) (11.2–16.4) (8.0–11.1) (15.1–18.2) (8.9–14.9) (17.5–23.8) (10.5–21.5) 
 Radiographic progression-free survival 
HR  0.84 
(0.62–1.13)  
0.3 
0.65 
(0.49–0.86)  
0.002 
0.56 
(0.41–0.76)  
0.0002 
0.68 
(0.50–0.91)  
0.01 
(95% CI)  
p Value 
Median, mo 5.2 2.9 5.6 3.3 5.7 3.4 9.1 5.6 
(95% CI) (3.0–5.6)  (2.8–5.6) (5.5–6.5) (2.9–5.6) (5.6–8.3) (2.8–5.6) (6.5–11.1) (2.9–8.7) 
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 Androgen receptor antagonists 
 Q1 
≤7 mo 
Q2 
≥8 to ≤16 mo 
Q3 
≥17 to ≤36 mo 
Q4 
>36 mo  
Treatment AA + P P AA + P P AA + P P AA + P P 
 (n = 155) (n = 95) (n = 179) (n = 85) (n = 167) (n = 82) (n = 170) (n = 82) 
 Overall survival 
HR  0.78 
(0.56–1.08) 
0.1 
0.99 
(0.71–1.38) 
0.9 
0.73 
(0.51–1.03) 
0.07 
0.57 
(0.40–0.81) 
0.002 
(95% CI)  
p Value 
Median, mo  11.9 10.7 14.9 13.5 16.2 10.7 19.2 11 
(95% CI) (10.0–16.0) (8.8–13.6) (12.8–16.8) (10.0–18.7) (14.2–18.2) (8.9–16.6) (16.7–23.3) (8.8–15.3) 
 Radiographic progression-free survival 
HR  0.76 
(0.55–1.05)  
0.09 
0.66 
(0.49–0.90)  
0.009 
0.68 
(0.50–0.93)  
0.01 
0.62 
(0.45–0.86)  
0.004 
(95% CI)  
p Value 
Median, mo 5.2 3.2 6.4 5.4 5.9 4.2 8.3 4.7 
(95% CI) (2.9–5.7) (2.8–5.6) (5.6–8.3) (2.8–6.6) (5.6–8.3) (2.9–6.8)  (5.6–11.0) (2.9–6.3) 
AA = abiraterone acetate; CI = confidence interval; GnRH = gonadotropin-releasing hormone; HR = hazard ratio; P = prednisone; Q = quartile. 
427 
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Table 2 – Clinical outcomes in COU-AA-302 patients with prior endocrine therapy exposure by duration in quartiles 428 
 GnRH agonists 
 Q1 
≤20 mo 
Q2 
≥21 to ≤37 mo 
Q3 
≥38 to ≤61 mo 
Q4 
>61 mo  
Treatment AA + P P AA + P P AA + P P AA + P P 
 (n = 119) (n = 133) (n = 145) (n = 137) (n = 127) (n = 127) (n = 139) (n = 130) 
 Overall survival 
HR  0.79 
(0.59–1.04) 
0.09 
0.69 
(0.52–0.91) 
0.01 
1.05 
(0.76–1.43) 
0.8 
0.78 
(0.57–1.06) 
0.1 
(95% CI)  
p Value 
Median, mo  26 21.8 33.2 30 34.5 38.5 43.5 34.9 
(95% CI) (22.2–33.5) (19.4–27.5) (29.8–40.4) (26.1–32.4) (28.5–44.0) (33.4–45.9) (36.8–48.9) (31.6–39.1) 
 Radiographic progression-free survival 
HR  0.52 
(0.37–0.72)  
< 0.0001 
0.46 
(0.33–0.62)  
 < 0.0001 
0.67 
(0.48–0.93)  
0.02 
0.46 
(0.34–0.64)  
< 0.0001 
(95% CI)  
p Value 
Median, mo 13.6 5.6 16.6 8.2 13.9 11 19.1 8.3 
(95% CI) (10.4–16·6)  (5.4–8.5) (13.6–22.0) (5.4–8.4) (11.2–19.3) (8.2–13.8) (16.4–27.8) (5.6–13.5) 
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 Androgen receptor antagonists 
 Q1 
≤7 mo 
Q2 
≥8 to ≤16 mo 
Q3 
≥17 to ≤33 mo 
Q4 
>33 mo  
Treatment AA + P P AA + P P AA + P P AA + P P 
 (n = 138) (n = 134) (n = 132) (n = 132) (n = 138) (n = 131) (n = 132) (n = 141) 
 Overall survival 
HR  0.62 
(0.47–0.82) 
0.0008 
0.83 
(0.62–1.11) 
0.2 
0.97 
(0.72–1.31) 
0.8 
0.88 
(0.65–1.20) 
0.4 
(95% CI)  
p Value 
Median, mo  32.5 23.1 31.9 28.7 34.7 35.9 41.4 37.7 
(95% CI) (26.4–35.4) (19.8–27.7) (26.6–39.0) (26.0–33.6) (31.2–38.7) (31.8–40.1) (34.4–48.9) (33.6–42.1) 
 Radiographic Progression-Free Survival 
HR  0.43 
(0.32–0.59)  
< 0.0001 
0.65 
(0.47–0.90)  
0.009 
0.52 
(0.37–0.72)  
< 0.0001 
0.5 
(0.36–0.69)  
< 0.0001 
(95% CI)  
p Value 
Median, mo 13.7 5.5 13.7 8.3 17.2 9.7 19.1 10.8 
(95% CI) (10.9–16.8) (3.8–8.2) (11.0–16.5) (8.0–10.9) (13.9–27.6) (7.9–11.4)  (13.8–27.6) (8.1–13.6) 
AA = abiraterone acetate; CI = confidence interval; GnRH = gonadotropin-releasing hormone; HR = hazard ratio; P = prednisone; Q = quartile. 
429 
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Supporting Table 1 – Prior endocrine therapies 445 
 446 
Method of castration  Androgen receptor antagonists 
 Buserelin 
 Buserelin acetate 
 Gonadotropin-releasing hormone analogues (undefined) 
 Goserelin 
 Goserelin acetate 
 Leuprorelin 
 Leuprorelin acetate 
 Orchiectomy 
 Triptorelin 
 Triptorelin acetate 
 Triptorelin embonate 
 Androgen receptor antagonists (undefined) 
 Bicalutamide 
 Cyproterone 
 Cyproterone acetate 
 Flutamide 
 Nilutamide 
 447 
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Supporting Table 2 – Interaction analysis 448 
COU-AA-301 
Parameter p Value 
Overall survival 
Treatment 0.1 
Duration 0.009 
Treatment* duration 0.4 
Radiographic progression-free survival 
Treatment 0.0006 
Duration < 0.0001 
Treatment* duration 0.7 
COU-AA-302 
Parameter p Value 
Overall survival 
Treatment 0.4 
Duration 0.002 
Treatment* duration 0.6 
Radiographic progression-free survival 
Treatment < 0.0001 
Duration 0.04 
Treatment* duration 0.7 
 449 
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Supporting Fig. 1 – Overall survival Kaplan-Meier estimates in COU-AA-301 patients with prior endocrine therapy 450 
exposure by duration in quartiles. A. Gonadotropin-releasing hormone agonists; B. androgen receptor antagonists. 451 
  452 
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 453 
AA = abiraterone acetate; CI = confidence interval; HR, hazard ratio; P = prednisone; OS = overall survival; rPFS = radiographic 454 
progression-free survival; Q = quartile. 455 
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Supporting Fig. 2 – Overall survival Kaplan-Meier estimates in COU-AA-302 patients with prior endocrine therapy 456 
exposure by duration in quartiles A. GnRH agonists; B. androgen receptor antagonists. 457 
  458 
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 459 
AA = abiraterone acetate; CI = confidence interval; HR, hazard ratio; P = prednisone; OS = overall survival; rPFS = radiographic 460 
progression-free survival; Q = quartile. 461 
